Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function

NCT00231894 is registered in ClinicalTrials.gov with Nathan Kline Institute for Psychiatric Research as lead sponsor.

NCT NCT00231894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00231894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2005
Completion date
January 31, 2010
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, diabetes, insulin resistance, schizophrenia